Asia Pacific Vaccine Market Report and Forecast 2025-2034
Description
The Asia Pacific vaccine market was valued at USD 4.56 Billion in 2024, driven by the growing incidence of infectious diseases, rising innovations in vaccine technology, and increasing immunization programs in the region. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 7.80% to reach nearly USD 9.66 Billion by 2034.
Asia Pacific Vaccine Market Overview
A vaccine provides immunity against various contagious diseases. It stimulates the production of antibodies to boost the immune system and prevent the risk or severity of symptoms. It is a crucial preventive and affordable medicine that eliminates the risk of hospitalization or prolonged illness from various diseases, such as hepatitis, influenzas, and Japanese Encephalitis, among others.
The Asia Pacific vaccine market is characterized by the increasing prevalence of infectious disease outbreaks, especially in developing regions, such as India, Indonesia, and Thailand, among others, that surges the demand for efficient vaccines. The growing economic development in countries like China and India is leading to increased healthcare spending, which also impacts the global vaccine market. Moreover, governments are increasingly boosting vaccine purchase to ensure free vaccination of children to boost the overall quality of life of their citizens. For example, in August 2019, the Indian government announced the expansion of coverage of the rotavirus vaccine to end fatality and morbidity associated with the virus by 2023. Other factors that shape the market dynamics include heightened public awareness about the benefits of vaccination, strategic partnerships, and rising advancements in vaccine production technologies.
Asia Pacific Vaccine Market Growth Drivers
Increased Focus on Indigenous Production of Vaccines to Affect the Market Landscape Significantly
In January 2024, Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board and a leading human vaccine manufacturer in India, launched its vaccine Havisure, the first indigenously developed Hepatitis A vaccine, in Hyderabad (India). Havisure is a two-dose vaccine, with the first dose recommended for children above 12 months of age, and the second dose is administered at least 6 months after the first dose. The vaccine is reported to show comparable efficacy and safety as the international standards of Hepatitis A vaccine and has undergone rigorous clinical trials in 8 centers. This surge in the launch of indigenous vaccines is a significant growth driver of the market and is likely to improve self-reliance, affordability, and access to vaccines in the Asia Pacific region.
Increasing Availability of Vaccines to Meet Rising Asia Pacific Vaccine Market Demand
The robust growth of the healthcare sector in the region is propelling the market growth. The emergence of various start-ups and international companies in countries such as China and India is escalating the availability of critical vaccines, boosting the market share. In addition, the rising affordability and quality of vaccines owing to extensive indigenous manufacturing are significantly contributing to the growth of the market. The initiation of vaccination drives and campaigns by non-profit and humanitarian organizations is further increasing the accessibility and demand for vaccines in the region.
Asia Pacific Vaccine Market Trends
The market is witnessing several trends and developments to improve the current scenario in the Asia Pacific. Some of the notable trends are as follows:
Innovations in Vaccine Technology
One of the major market trends is the growth in vaccine technology, including the advancement in recombinant and conjugate vaccines and the development of mRNA vaccines, which are improving efficacy and safety. These advancements augment market demand and also draw significant investments in the market.
Increased Focus on Pediatric Vaccination
The rising emphasis on pediatric vaccination programs is one of the significant market trends propelling the market demand for vaccines that can prevent diseases like measles, mumps, and rubella. Further, the increasing government investment to ensure high immunization coverage among children boosts the Asia Pacific market share.
Improvements in Healthcare Infrastructure
In Asia Pacific, the expanding healthcare infrastructure, particularly in emerging economies, is a major market trend that is facilitating better vaccine distribution. Improvements in storage facilities and cold chain logistics further bolster the market growth.
Rise of Adult and Travel Vaccinations
There is a growing demand for adult and travel vaccinations for diseases like influenza and hepatitis. This market trend is driven by rising travel and mobility for education, business, and leisure, increased awareness, and the rising development of new and more effective vaccines.
Asia Pacific Vaccine Market Segmentation
“Asia Pacific Vaccine Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Composition
Market Segmentation Based on Type is Anticipated to Witness Substantial Growth
The market segmentation based on the vaccine type includes recombinant and conjugate vaccines, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. The recombinant and conjugate vaccines segment represents a considerable share of the market due to their high efficacy and safety and their increased adoption in national immunization programs to prevent common and serious infections such as hepatitis B and meningococcal disease. On the other hand, inactivated vaccines are widely used for immunocompromised individuals due to their strong safety profile.
Asia Pacific Vaccine Market Analysis by Region
Based on the region, the market is segmented into China, Japan, India, ASEAN, and Australia, among others. In China, the market is poised to witness significant growth owing to increasing research and development (R&D) activities in the region. Moreover, the extensive production of vaccines, along with the presence of several leading companies is bolstering the market value. The introduction of various government initiatives to enhance capabilities in the biotechnology sector is augmenting the market growth. Furthermore, leading companies are increasingly investing in the country for the development of novel vaccines owing to the availability of cost-effective raw materials and highly skilled laborers, which is providing further impetus to the growth of the market.
Leading Players in the Asia Pacific Vaccine Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the key players. The major companies in the market are as follows:
CSL
This global biotechnology company, Commonwealth Serum Laboratories (CSL) Limited, is headquartered in Melbourne, Australia, and is popular for its influenza and COVID-19 vaccines. CSL boasts robust R&D capabilities and an extensive distribution network in the Asia Pacific region.
Bharat Biotech International Limited
Indian multinational biotechnology company Bharat Biotech International Limited stands as a leading manufacturer of high-quality vaccines and bio-therapeutics. It is known for developing Covaxin (COVID-19), Rotavac (rotavirus), and Typbar TCV (typhoid) vaccines, and significantly contributes to the Asia Pacific vaccine market share.
GSK plc
GSK plc (GlaxoSmithKline), a multinational pharmaceutical and biotechnology company, holds a strong portfolio that includes vaccines for diseases such as hepatitis, influenza, human papillomavirus (HPV), and meningitis, among others.
Pfizer Inc.
Pharmaceutical giant Pfizer Inc. has a prominent presence in the market due to its strong manufacturing capabilities and wide distribution network. Pfizer is known for its COVID-19 vaccine, Comirnaty, which it developed in collaboration with BioNTech.
Other key players in the market include AstraZeneca PLC, Biological E. Limited, Serum Institute of India, Takeda, Merck & Co., Inc., Abbott, and Sanofi.
Key Questions Answered in the Asia Pacific Vaccine Market Report
Asia Pacific Vaccine Market Overview
A vaccine provides immunity against various contagious diseases. It stimulates the production of antibodies to boost the immune system and prevent the risk or severity of symptoms. It is a crucial preventive and affordable medicine that eliminates the risk of hospitalization or prolonged illness from various diseases, such as hepatitis, influenzas, and Japanese Encephalitis, among others.
The Asia Pacific vaccine market is characterized by the increasing prevalence of infectious disease outbreaks, especially in developing regions, such as India, Indonesia, and Thailand, among others, that surges the demand for efficient vaccines. The growing economic development in countries like China and India is leading to increased healthcare spending, which also impacts the global vaccine market. Moreover, governments are increasingly boosting vaccine purchase to ensure free vaccination of children to boost the overall quality of life of their citizens. For example, in August 2019, the Indian government announced the expansion of coverage of the rotavirus vaccine to end fatality and morbidity associated with the virus by 2023. Other factors that shape the market dynamics include heightened public awareness about the benefits of vaccination, strategic partnerships, and rising advancements in vaccine production technologies.
Asia Pacific Vaccine Market Growth Drivers
Increased Focus on Indigenous Production of Vaccines to Affect the Market Landscape Significantly
In January 2024, Indian Immunologicals Ltd (IIL), a subsidiary of the National Dairy Development Board and a leading human vaccine manufacturer in India, launched its vaccine Havisure, the first indigenously developed Hepatitis A vaccine, in Hyderabad (India). Havisure is a two-dose vaccine, with the first dose recommended for children above 12 months of age, and the second dose is administered at least 6 months after the first dose. The vaccine is reported to show comparable efficacy and safety as the international standards of Hepatitis A vaccine and has undergone rigorous clinical trials in 8 centers. This surge in the launch of indigenous vaccines is a significant growth driver of the market and is likely to improve self-reliance, affordability, and access to vaccines in the Asia Pacific region.
Increasing Availability of Vaccines to Meet Rising Asia Pacific Vaccine Market Demand
The robust growth of the healthcare sector in the region is propelling the market growth. The emergence of various start-ups and international companies in countries such as China and India is escalating the availability of critical vaccines, boosting the market share. In addition, the rising affordability and quality of vaccines owing to extensive indigenous manufacturing are significantly contributing to the growth of the market. The initiation of vaccination drives and campaigns by non-profit and humanitarian organizations is further increasing the accessibility and demand for vaccines in the region.
Asia Pacific Vaccine Market Trends
The market is witnessing several trends and developments to improve the current scenario in the Asia Pacific. Some of the notable trends are as follows:
Innovations in Vaccine Technology
One of the major market trends is the growth in vaccine technology, including the advancement in recombinant and conjugate vaccines and the development of mRNA vaccines, which are improving efficacy and safety. These advancements augment market demand and also draw significant investments in the market.
Increased Focus on Pediatric Vaccination
The rising emphasis on pediatric vaccination programs is one of the significant market trends propelling the market demand for vaccines that can prevent diseases like measles, mumps, and rubella. Further, the increasing government investment to ensure high immunization coverage among children boosts the Asia Pacific market share.
Improvements in Healthcare Infrastructure
In Asia Pacific, the expanding healthcare infrastructure, particularly in emerging economies, is a major market trend that is facilitating better vaccine distribution. Improvements in storage facilities and cold chain logistics further bolster the market growth.
Rise of Adult and Travel Vaccinations
There is a growing demand for adult and travel vaccinations for diseases like influenza and hepatitis. This market trend is driven by rising travel and mobility for education, business, and leisure, increased awareness, and the rising development of new and more effective vaccines.
Asia Pacific Vaccine Market Segmentation
“Asia Pacific Vaccine Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Composition
- Combination Vaccine
- Mono Vaccine
- Recombinant and Conjugate Vaccine
- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Others
- Pediatric
- Geriatric
- Adult
- Pneumococcal Disease
- Influenza
- Typhoid
- Rabies
- Yellow Fever
- Human Papilloma Virus (HPV)
- Meningococcal Disease
- Varicella, Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DPT)
- Polio
- Hepatitis
- JE (Japanese Encephalitis)
- Others
- Injectable
- Oral
- Nasal
- China
- Japan
- India
- ASEAN
- Australia
- Others
Market Segmentation Based on Type is Anticipated to Witness Substantial Growth
The market segmentation based on the vaccine type includes recombinant and conjugate vaccines, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. The recombinant and conjugate vaccines segment represents a considerable share of the market due to their high efficacy and safety and their increased adoption in national immunization programs to prevent common and serious infections such as hepatitis B and meningococcal disease. On the other hand, inactivated vaccines are widely used for immunocompromised individuals due to their strong safety profile.
Asia Pacific Vaccine Market Analysis by Region
Based on the region, the market is segmented into China, Japan, India, ASEAN, and Australia, among others. In China, the market is poised to witness significant growth owing to increasing research and development (R&D) activities in the region. Moreover, the extensive production of vaccines, along with the presence of several leading companies is bolstering the market value. The introduction of various government initiatives to enhance capabilities in the biotechnology sector is augmenting the market growth. Furthermore, leading companies are increasingly investing in the country for the development of novel vaccines owing to the availability of cost-effective raw materials and highly skilled laborers, which is providing further impetus to the growth of the market.
Leading Players in the Asia Pacific Vaccine Market
The key features of the market report comprise patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the key players. The major companies in the market are as follows:
CSL
This global biotechnology company, Commonwealth Serum Laboratories (CSL) Limited, is headquartered in Melbourne, Australia, and is popular for its influenza and COVID-19 vaccines. CSL boasts robust R&D capabilities and an extensive distribution network in the Asia Pacific region.
Bharat Biotech International Limited
Indian multinational biotechnology company Bharat Biotech International Limited stands as a leading manufacturer of high-quality vaccines and bio-therapeutics. It is known for developing Covaxin (COVID-19), Rotavac (rotavirus), and Typbar TCV (typhoid) vaccines, and significantly contributes to the Asia Pacific vaccine market share.
GSK plc
GSK plc (GlaxoSmithKline), a multinational pharmaceutical and biotechnology company, holds a strong portfolio that includes vaccines for diseases such as hepatitis, influenza, human papillomavirus (HPV), and meningitis, among others.
Pfizer Inc.
Pharmaceutical giant Pfizer Inc. has a prominent presence in the market due to its strong manufacturing capabilities and wide distribution network. Pfizer is known for its COVID-19 vaccine, Comirnaty, which it developed in collaboration with BioNTech.
Other key players in the market include AstraZeneca PLC, Biological E. Limited, Serum Institute of India, Takeda, Merck & Co., Inc., Abbott, and Sanofi.
Key Questions Answered in the Asia Pacific Vaccine Market Report
- What was the Asia Pacific vaccine market value in 2024?
- What is the Asia Pacific vaccine market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on the composition?
- What is the market breakup based on the type?
- What is the market breakup by age?
- What is market segmentation based on the indication?
- What are the different routes of administration available in the market?
- What are the major factors aiding the Asia Pacific vaccine market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of infectious diseases affect the market landscape?
- What are the major Asia Pacific vaccine market trends?
- How does the rising economic growth in the Asia Pacific region impact the market size?
- Which vaccine composition will dominate the market share in the Asia Pacific?
- Which vaccine type is expected to have a high market value in the coming years?
- Which age group will cover the highest market share?
- Which indication will experience the highest demand in the market segment?
- Which route of administration is projected to contribute to the highest market growth?
- Who are the key players involved in the Asia Pacific vaccine market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Vaccine Market Overview
- 3.1 Global Vaccine Market
- 3.1.1 Global Vaccine Market Historical Value (2018-2024)
- 3.1.2 Global Vaccine Market Forecast Value (2025-2034)
- 3.2 Asia Pacific Vaccine Market
- 3.2.1 Asia Pacific Vaccine Market Historical Value (2018-2024)
- 3.2.2 Asia Pacific Vaccine Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Asia Pacific Vaccine Market, Epidemiology Snapshot
- 5.1 Overview of Asia Pacific Disease Incidence Number (2018-2034)
- 5.2 Incidence Number, By Indication (2018-2034)
- 5.2.1 Pneumococcal Disease
- 5.2.2 Influenza
- 5.2.3 Typhoid
- 5.2.4 Rabies
- 5.2.5 Yellow Fever
- 5.2.6 Human Papilloma Virus (HPV)
- 5.2.7 Meningococcal Disease
- 5.2.8 Varicella, Measles, Mumps, and Rubella
- 5.2.9 Diphtheria, Pertussis, and Tetanus (DPT)
- 5.2.10 Polio
- 5.2.11 Hepatitis
- 5.2.12 JE (Japanese Encephalitis)
- 5.2.13 Others
- 6 Asia Pacific Vaccine Market Landscape*
- 6.1 Asia Pacific Vaccine Market: Developers Landscape
- 6.1.1 Analysis by Year of Establishment
- 6.1.2 Analysis by Company Size
- 6.1.3 Analysis by Region
- 6.2 Asia Pacific Vaccine Market: Product Landscape
- 6.2.1 Analysis by Composition
- 6.2.2 Analysis by Type
- 6.2.3 Analysis by Indication
- 6.2.4 Analysis by Route of Administration
- 7 Asia Pacific Vaccine Market Dynamics
- 7.1 Market Drivers and Constraints
- 7.2 SWOT Analysis
- 7.2.1 Strengths
- 7.2.2 Weaknesses
- 7.2.3 Opportunities
- 7.2.4 Threats
- 7.3 PESTEL Analysis
- 7.3.1 Political
- 7.3.2 Environmental
- 7.3.3 Social
- 7.3.4 Technological
- 7.3.5 Ethical
- 7.3.6 Legal
- 7.4 Porter’s Five Forces Model
- 7.4.1 Bargaining Power of Suppliers
- 7.4.2 Bargaining Power of Buyers
- 7.4.3 Threat of New Entrants
- 7.4.4 Threat of Substitutes
- 7.4.5 Degree of Rivalry
- 7.5 Key Demand Indicators
- 7.6 Key Price Indicators
- 7.7 Industry Events, Initiatives, and Trends
- 7.8 Value Chain Analysis
- 8 Asia Pacific Vaccine Market Segmentation (218-2034)
- 8.1 Asia Pacific Vaccine Market (2018-2034) by Composition
- 8.1.1 Market Overview
- 8.1.2 Combination Vaccine
- 8.1.3 Mono Vaccine
- 8.2 Asia Pacific Vaccine Market (2018-2034) by Type
- 8.2.1 Market Overview
- 8.2.2 Recombinant and Conjugate Vaccine
- 8.2.3 Inactivated Vaccines
- 8.2.4 Live Attenuated Vaccines
- 8.2.5 Toxoid Vaccines
- 8.2.6 Others
- 8.3 Asia Pacific Vaccine Market (2018-2034) by Age
- 8.3.1 Market Overview
- 8.3.2 Pediatric
- 8.3.3 Geriatric
- 8.3.4 Adult
- 8.4 Asia Pacific Vaccine Market (2018-2034) by Indication
- 8.4.1 Market Overview
- 8.4.2 Pneumococcal Disease
- 8.4.3 Influenza
- 8.4.4 Typhoid
- 8.4.5 Rabies
- 8.4.6 Yellow Fever
- 8.4.7 Human Papilloma Virus (HPV)
- 8.4.8 Meningococcal Disease
- 8.4.9 Varicella, Measles, Mumps, and Rubella
- 8.4.10 Diphtheria, Pertussis, and Tetanus (DPT)
- 8.4.11 Polio
- 8.4.12 Hepatitis
- 8.4.13 JE (Japanese Encephalitis)
- 8.4.14 Others
- 8.5 Asia Pacific Vaccine Market (2018-2034) by Route of Administration
- 8.5.1 Market Overview
- 8.5.2 Injectable
- 8.5.3 Oral
- 8.5.4 Nasal
- 8.6 Asia Pacific Vaccine Market (2018-2034) by Country
- 8.6.1 Market Overview
- 8.6.2 China
- 8.6.3 Japan
- 8.6.4 India
- 8.6.5 ASEAN
- 8.6.6 Australia
- 8.6.7 Others
- 9 China Vaccine Market Segmentation (218-2034)
- 9.1 China Vaccine Market (2018-2034) by Composition
- 9.1.1 Market Overview
- 9.1.2 Combination Vaccine
- 9.1.3 Mono Vaccine
- 9.2 China Vaccine Market (2018-2034) by Type
- 9.2.1 Market Overview
- 9.2.2 Recombinant and Conjugate Vaccine
- 9.2.3 Inactivated Vaccines
- 9.2.4 Live Attenuated Vaccines
- 9.2.5 Toxoid Vaccines
- 9.2.6 Others
- 9.3 China Vaccine Market (2018-2034) by Age
- 9.3.1 Market Overview
- 9.3.2 Pediatric
- 9.3.3 Geriatric
- 9.3.4 Adult
- 9.4 China Vaccine Market (2018-2034) by Indication
- 9.4.1 Market Overview
- 9.4.2 Pneumococcal Disease
- 9.4.3 Influenza
- 9.4.4 Typhoid
- 9.4.5 Rabies
- 9.4.6 Yellow Fever
- 9.4.7 Human Papilloma Virus (HPV)
- 9.4.8 Meningococcal Disease
- 9.4.9 Varicella, Measles, Mumps, and Rubella
- 9.4.10 Diphtheria, Pertussis, and Tetanus (DPT)
- 9.4.11 Polio
- 9.4.12 Hepatitis
- 9.4.13 JE (Japanese Encephalitis)
- 9.4.14 Others
- 9.5 China Vaccine Market (2018-2034) by Route of Administration
- 9.5.1 Market Overview
- 9.5.2 Injectable
- 9.5.3 Oral
- 9.5.4 Nasal
- 10 Japan Vaccine Market Segmentation (218-2034)
- 10.1 Japan Vaccine Market (2018-2034) by Composition
- 10.1.1 Market Overview
- 10.1.2 Combination Vaccine
- 10.1.3 Mono Vaccine
- 10.2 Japan Vaccine Market (2018-2034) by Type
- 10.2.1 Market Overview
- 10.2.2 Recombinant and Conjugate Vaccine
- 10.2.3 Inactivated Vaccines
- 10.2.4 Live Attenuated Vaccines
- 10.2.5 Toxoid Vaccines
- 10.2.6 Others
- 10.3 Japan Vaccine Market (2018-2034) by Age
- 10.3.1 Market Overview
- 10.3.2 Pediatric
- 10.3.3 Geriatric
- 10.3.4 Adult
- 10.4 Japan Vaccine Market (2018-2034) by Indication
- 10.4.1 Market Overview
- 10.4.2 Pneumococcal Disease
- 10.4.3 Influenza
- 10.4.4 Typhoid
- 10.4.5 Rabies
- 10.4.6 Yellow Fever
- 10.4.7 Human Papilloma Virus (HPV)
- 10.4.8 Meningococcal Disease
- 10.4.9 Varicella, Measles, Mumps, and Rubella
- 10.4.10 Diphtheria, Pertussis, and Tetanus (DPT)
- 10.4.11 Polio
- 10.4.12 Hepatitis
- 10.4.13 JE (Japanese Encephalitis)
- 10.4.14 Others
- 10.5 Japan Vaccine Market (2018-2034) by Route of Administration
- 10.5.1 Market Overview
- 10.5.2 Injectable
- 10.5.3 Oral
- 10.5.4 Nasal
- 11 India Vaccine Market Segmentation (218-2034)
- 11.1 India Vaccine Market (2018-2034) by Composition
- 11.1.1 Market Overview
- 11.1.2 Combination Vaccine
- 11.1.3 Mono Vaccine
- 11.2 India Vaccine Market (2018-2034) by Type
- 11.2.1 Market Overview
- 11.2.2 Recombinant and Conjugate Vaccine
- 11.2.3 Inactivated Vaccines
- 11.2.4 Live Attenuated Vaccines
- 11.2.5 Toxoid Vaccines
- 11.2.6 Others
- 11.3 India Vaccine Market (2018-2034) by Age
- 11.3.1 Market Overview
- 11.3.2 Pediatric
- 11.3.3 Geriatric
- 11.3.4 Adult
- 11.4 India Vaccine Market (2018-2034) by Indication
- 11.4.1 Market Overview
- 11.4.2 Pneumococcal Disease
- 11.4.3 Influenza
- 11.4.4 Typhoid
- 11.4.5 Rabies
- 11.4.6 Yellow Fever
- 11.4.7 Human Papilloma Virus (HPV)
- 11.4.8 Meningococcal Disease
- 11.4.9 Varicella, Measles, Mumps, and Rubella
- 11.4.10 Diphtheria, Pertussis, and Tetanus (DPT)
- 11.4.11 Polio
- 11.4.12 Hepatitis
- 11.4.13 JE (Japanese Encephalitis)
- 11.4.14 Others
- 11.5 India Vaccine Market (2018-2034) by Route of Administration
- 11.5.1 Market Overview
- 11.5.2 Injectable
- 11.5.3 Oral
- 11.5.4 Nasal
- 12 ASEAN Vaccine Market Segmentation (218-2034)
- 12.1 ASEAN Vaccine Market (2018-2034) by Composition
- 12.1.1 Market Overview
- 12.1.2 Combination Vaccine
- 12.1.3 Mono Vaccine
- 12.2 ASEAN Vaccine Market (2018-2034) by Type
- 12.2.1 Market Overview
- 12.2.2 Recombinant and Conjugate Vaccine
- 12.2.3 Inactivated Vaccines
- 12.2.4 Live Attenuated Vaccines
- 12.2.5 Toxoid Vaccines
- 12.2.6 Others
- 12.3 ASEAN Vaccine Market (2018-2034) by Age
- 12.3.1 Market Overview
- 12.3.2 Pediatric
- 12.3.3 Geriatric
- 12.3.4 Adult
- 12.4 ASEAN Vaccine Market (2018-2034) by Indication
- 12.4.1 Market Overview
- 12.4.2 Pneumococcal Disease
- 12.4.3 Influenza
- 12.4.4 Typhoid
- 12.4.5 Rabies
- 12.4.6 Yellow Fever
- 12.4.7 Human Papilloma Virus (HPV)
- 12.4.8 Meningococcal Disease
- 12.4.9 Varicella, Measles, Mumps, and Rubella
- 12.4.10 Diphtheria, Pertussis, and Tetanus (DPT)
- 12.4.11 Polio
- 12.4.12 Hepatitis
- 12.4.13 JE (Japanese Encephalitis)
- 12.4.14 Others
- 12.5 ASEAN Vaccine Market (2018-2034) by Route of Administration
- 12.5.1 Market Overview
- 12.5.2 Injectable
- 12.5.3 Oral
- 12.5.4 Nasal
- 13 Australia Vaccine Market Segmentation (218-2034)
- 13.1 Australia Vaccine Market (2018-2034) by Composition
- 13.1.1 Market Overview
- 13.1.2 Combination Vaccine
- 13.1.3 Mono Vaccine
- 13.2 Australia Vaccine Market (2018-2034) by Type
- 13.2.1 Market Overview
- 13.2.2 Recombinant and Conjugate Vaccine
- 13.2.3 Inactivated Vaccines
- 13.2.4 Live Attenuated Vaccines
- 13.2.5 Toxoid Vaccines
- 13.2.6 Others
- 13.3 Australia Vaccine Market (2018-2034) by Age
- 13.3.1 Market Overview
- 13.3.2 Pediatric
- 13.3.3 Geriatric
- 13.3.4 Adult
- 13.4 Australia Vaccine Market (2018-2034) by Indication
- 13.4.1 Market Overview
- 13.4.2 Pneumococcal Disease
- 13.4.3 Influenza
- 13.4.4 Typhoid
- 13.4.5 Rabies
- 13.4.6 Yellow Fever
- 13.4.7 Human Papilloma Virus (HPV)
- 13.4.8 Meningococcal Disease
- 13.4.9 Varicella, Measles, Mumps, and Rubella
- 13.4.10 Diphtheria, Pertussis, and Tetanus (DPT)
- 13.4.11 Polio
- 13.4.12 Hepatitis
- 13.4.13 JE (Japanese Encephalitis)
- 13.4.14 Others
- 13.5 Australia Vaccine Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Injectable
- 13.5.3 Oral
- 13.5.4 Nasal
- 14 Regulatory Framework
- 14.1 Regulatory Overview
- 14.2 India CDSCO
- 14.3 Japan PMDA
- 14.4 Others
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding and Investment Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Strategic Initiatives
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership and Collaborations
- 19.3 Analysis by Joint Ventures
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Region
- 20 Supplier Landscape
- 20.1 Market Share by Top 5 Companies
- 20.2 CSL
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisitions
- 20.2.5 Certifications
- 20.3 Bharat Biotech International Limited
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisitions
- 20.3.5 Certifications
- 20.4 GSK plc
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisitions
- 20.4.5 Certifications
- 20.5 Pfizer Inc .
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisitions
- 20.5.5 Certifications
- 20.6 AstraZeneca PLC
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisitions
- 20.6.5 Certifications
- 20.7 Biological E. Limited
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisitions
- 20.7.5 Certifications
- 20.8 Serum Institute of India
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisitions
- 20.8.5 Certifications
- 20.9 Takeda
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisitions
- 20.9.5 Certifications
- 20.10 Merck & Co., Inc .
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisitions
- 20.10.5 Certifications
- 20.11 Abbott
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisitions
- 20.11.5 Certifications
- 20.12 Sanofi
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisitions
- 20.12.5 Certifications
- 21 Vaccine Treatment Drugs - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
